Susceptibilities of clinical and laboratory isolates of Blastomyces dermatitidis to ketoconazole, itraconazole, and fluconazole

被引:17
作者
Chapman, SW [1 ]
Rogers, PD
Rinaldi, MG
Sullivan, DC
机构
[1] Univ Mississippi, Med Ctr, Dept Med,Sch Med, Div Infect Dis, Jackson, MS 39216 USA
[2] Univ Mississippi, Med Ctr, Sch Med, Dept Microbiol, Jackson, MS 39216 USA
[3] Univ Mississippi, Med Ctr, Sch Pharm, Dept Clin Pharm Practice, Jackson, MS 39216 USA
[4] Univ Texas, Hlth Sci Ctr, Sch Med, Dept Pathol,Fungus Testing Lab, San Antonio, TX 78284 USA
关键词
D O I
10.1128/AAC.42.4.978
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Eighteen isolates of Blastomyces dermatitidis were evaluated for their in vitro susceptibilities to ketoconazole, itraconazole, and fluconazole. The MIC ranges were 0.1 to 0.4 mu g/ml for ketoconazole, less than or equal to 0.018 to 0.07 mu g/ml for itraconazole, and 2.5 to 4.0 mu g/ml for fluconazole. The ranges for the minimal lethal concentrations were 0.2 to 0.8 mu g/ml for ketoconazole, less than or equal to 0.018 to 0.07 mu g/ml for itraconazole, and 10 to 40 mu g/ml for fluconazole. Itraconazole was the most active agent against B. dermatitidis in vitro, while fluconazole was the least active. These results correlate with the clinical efficacies noted to date with doses of these agents used to treat blastomycosis.
引用
收藏
页码:978 / 980
页数:3
相关论文
共 20 条
[1]   Histoplasmosis and blastomycosis [J].
Bradsher, RW .
CLINICAL INFECTIOUS DISEASES, 1996, 22 :S102-S111
[2]   KETOCONAZOLE THERAPY FOR ENDEMIC BLASTOMYCOSIS [J].
BRADSHER, RW ;
RICE, DC ;
ABERNATHY, RS .
ANNALS OF INTERNAL MEDICINE, 1985, 103 (06) :872-879
[3]  
CHAPMAN SW, 1995, PRINCIPLES PRACTICE, P2353
[5]   ITRACONAZOLE THERAPY FOR BLASTOMYCOSIS AND HISTOPLASMOSIS [J].
DISMUKES, WE ;
BRADSHER, RW ;
CLOUD, GC ;
KAUFFMAN, CA ;
CHAPMAN, SW ;
GEORGE, RB ;
STEVENS, DA ;
GIRARD, WM ;
SAAG, MS ;
BOWLESPATTON, C .
AMERICAN JOURNAL OF MEDICINE, 1992, 93 (05) :489-497
[6]   Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi [J].
EspinelIngroff, A ;
Bartlett, M ;
Bowden, R ;
Chin, NX ;
Cooper, C ;
Fothergill, A ;
McGinnis, MR ;
Menezes, P ;
Messer, SA ;
Nelson, PW ;
Odds, FC ;
Pasarell, L ;
Peter, J ;
Pfaller, MA ;
Rex, JH ;
Rinaldi, MG ;
Shankland, GS ;
Walsh, TJ ;
Weitzman, I .
JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (01) :139-143
[7]   EVALUATION OF 80-PERCENT INHIBITION STANDARDS FOR THE DETERMINATION OF FLUCONAZOLE MINIMUM INHIBITORY CONCENTRATIONS IN 3 LABORATORIES [J].
ESPINELINGROFF, A ;
STEELEMOORE, L ;
GALGIANI, JN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1994, 20 (02) :81-86
[8]  
GANER A, 1987, REV INFECT DIS, V9, pS77
[9]   MEDIUM FOR SUSCEPTIBILITY TESTING AND YEAST PHASE CONVERSION OF BLASTOMYCES-DERMATITIDIS [J].
KURUP, VP ;
RESNICK, A ;
ROSE, HD .
MYCOPATHOLOGIA, 1986, 95 (01) :25-28
[10]  
MCGINNIS MR, 1986, ANTIBIOTICS LAB MED, P176